In our “vs” blog series, we explain the most important differences between the most common weight loss injections and tablets. In this article, you’ll find a detailed overview of Wegovy vs Ozempic, including approval, dosage, and who they’re intended for.
What are the main Wegovy Ozempic differences?
Same active ingredient, different approval: Both Ozempic and Wegovy contain semaglutide and work by mimicking the naturally occurring gut hormone GLP-1 (glucagon-like peptide-1). Ozempic is one of the best-known medications associated with medical weight loss—however, it was originally developed and approved for the treatment of type 2 diabetes. Weight loss is considered a side effect.
If semaglutide is prescribed specifically for weight management, Wegovy may be an option when there is a medical indication. Wegovy contains the same active ingredient and is also injected once weekly using a prefilled pen—but it is available in higher doses. This is one of the key Wegovy Ozempic differences.
How do Wegovy and Ozempic work?
Both medications work via the same mechanism: the active ingredient semaglutide mimics GLP-1, a hormone produced in the gut. It:
- regulates satiety signals in the brain,
- slows gastric emptying, and
- stimulates insulin secretion.
This can lead to:
- less hunger,
- reduced food intake, and
- steady weight loss.
Because GLP-1 also promotes insulin secretion, blood sugar control can improve in people with diabetes—which is Ozempic’s primary treatment goal. If you’d like a clearer picture of how weight loss injections interact with blood sugar and how diet can support stability, this article may help: How “weight loss injections” affect blood sugar and how nutrition can stabilize it.
Who is Wegovy or Ozempic suitable for?
Even though both contain the same active ingredient, Wegovy and Ozempic differ significantly in approval and dosage—an important factor when considering Wegovy or Ozempic.
- Ozempic is approved for treating type 2 diabetes. It lowers blood sugar and may also support weight reduction.
- Wegovy is explicitly approved for weight loss in people with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity (e.g., high blood pressure).
Switching between medications
Important to consider: Ozempic is only approved for type 2 diabetes
Ozempic has received a lot of public attention due to its effect on body weight. What is often overlooked is that it is not approved for weight loss, but exclusively for diabetes therapy. Studies on its effectiveness were therefore conducted with people with diabetes.
Using Ozempic outside its approved indication—i.e., off-label use for weight loss—has contributed to supply shortages. This can become a serious issue for people who rely on the medication for diabetes management. Any switch should be evaluated holistically and made only with a clear medical indication.
Pros and cons of switching
Switching between Ozempic and Wegovy can make sense—but only under medical supervision.
Benefits of switching from Ozempic to Wegovy
- Higher available dose specifically for weight reduction
- Approved for obesity treatment, even without diabetes
- Clinical studies support targeted effectiveness in overweight and obesity
Potential downsides of switching from Ozempic to Wegovy
- Not yet consistently available across Germany
- Possible side effects: nausea, diarrhea, constipation
- Possible risks for people with diabetes:
- No official approval for diabetes
- Unclear blood sugar effects at higher doses: Wegovy uses higher semaglutide doses than Ozempic. This could lead to stronger blood sugar effects and may increase the risk of hypoglycemia in some situations.
- No dedicated studies on blood sugar effects at higher doses in people with diabetes
Expected weight loss: Wegovy vs Ozempic
Based on clinical studies, the following weight loss outcomes may be possible:
- With Wegovy, weight loss of 15% or more over 12–18 months may be possible, depending on starting weight and lifestyle.
- Ozempic can also lead to weight reduction, typically around 5–10%, depending on dose and individual response.
Success always also depends on diet, movement, and comorbidities. If you want a transparent overview of what to expect before starting therapy (including side effects and the usual process), see: Therapy process and side effects: before you start.
More comparisons at a glance
If you’d like to compare beyond Wegovy vs Ozempic, this overview may help depending on which medication is most relevant for you:
| Comparison | What it covers | Link |
|---|---|---|
| Wegovy vs Mounjaro | Differences in mechanism, dosing, and target groups | View comparison |
| Mounjaro vs Ozempic | Semaglutide vs tirzepatide: what does it mean in practice? | View comparison |
| Wegovy vs Saxenda | GLP-1 comparison: use, dosing, expected effect | View comparison |
Summary: Wegovy vs Ozempic
Same active ingredient, different target groups—that’s the core of the Wegovy Ozempic differences:
- Ozempic: primarily for people with type 2 diabetes to support blood sugar control; available in doses up to 1 mg/week
- Wegovy: specifically for medical weight loss in obesity; available in doses up to 2.4 mg/week
Both medications are prescription-only and should be used only under medical supervision.
Note: This article is for informational purposes only and does not replace medical advice.
If you want to explore which type of medical support may fit your situation, you can find an overview here: Medical weight loss: A sustainable solution for obesity?. If you’re specifically interested in Wegovy, you’ll find key information about therapy and medical use here: Lose weight safely and effectively with the weight loss injections.
Sources
- Pratley R.E., Aroda V.R, Lingvay I., Ludemann J, Andreassen C., Navarria A, et al. 2018. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 6(4), 275–86.
- Wilding, J.P.H. et. al. 2021. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine.
- Jastreboff, A. M., et. al. 2022. Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine.
- Pharmazeutische Zeitung. 09.02.2023. Fakten zu den „Fettweg-Spritzen“.
- Gelbe Liste. 30.07.2021. GLP-1-Rezeptoragonisten (Inkretinmimetika).
- Pharmazeutische Zeitung. 14.04.2023. Arzneistoffe zum Abnehmen im Kommen.
- European Medicines Agency. 08.01.2025. Wegovy: EPAR – Product Information.
- European Medicines Agency. 13.02.2025. Ozempic: EPAR – Product Information.